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Abstract
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the major adult liver cancers.
The existence of combined hepatocellular-cholangiocarcinoma (CHC), a histopathological
intermediate form between HCC and CC, suggests phenotypic overlap between these tumors.
Here, we applied an integrative oncogenomic approach to address the clinical and functional
implications of the overlapped phenotype between these tumors. By performing gene expression
profiling of human HCC, CHC, and CC, we identified a novel HCC subtype, namely, CC-like
HCC (CLHCC), which expressed CC-like traits (CC signature). As like CC and CHC, CLHCC
showed aggressive phenotype with shorter recurrence-free and overall survival. In addition, we
found that CLHCC coexpressed embryonic stem cell-like expression traits (ES signature)
suggesting its derivation from bipotent hepatic progenitor cells. By comparing the expression of
CC signature with previous ES-like, hepatoblast-like, or proliferation-related traits, we observed
that that the prognostic value of the CC signatures is independent of the expression of those
signatures. In conclusion, we suggest that the acquisition of CC like-expression traits play a
critical role in the heterogeneous progression of HCC.
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Introduction
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the major primary liver
cancers in adults. HCC is enormously heterogeneous with dismal clinical outcome (1), while
CC is more difficult to diagnose and to treat compared with HCC showing worse prognosis
(2). In addition, a rare form of combined hepatocellular-cholangiocarcinoma (CHC) has
been reported to have intermediate characteristics between HCC and CC (3). Most HCC and
CC are believed to be derived from hepatocytes and cholangiocytes, respectively.
Meanwhile, CHC have been suggested to be derived from bipotential liver stem cells which
can differentiate into either hepatic or biliary progenitor cells (4). In addition, several studies
have suggested the stem/progenitor cell origin of liver cancers including HCC (5, 6), CC (7),
and cholangiolocellular carcinoma (8). Such heterogeneous differentiation status of cellular
origin suggests the phenotypic overlap between HCC, CHC, and CC.
Liver stem cells have bipotential to differentiate into either hepatic or biliary progenitor cells
(9, 10). However, the cancer phenotypes derived from the biliary committed cells during
developmental hierarchy were not investigated thoroughly. In this study, to address the
biological and clinical implications of the overlapped phenotype between biliary and hepatic
cell-traits in liver cancer, we applied an integrative genomic approach by comparing the
expression profiles of HCC, CHC, and CC. By calculating the expression levels of CC-like
traits (CC signature), we identified a novel subtype of HCC, namely CC-like HCC
(CLHCC) which might be derived from biliary lineage cells. Further evaluation of the CC-
like trait with the previous stem cell-derived traits such as embryonic stem (ES) cell-like
(11) and hepatoblast (HB)-like (12) signatures was helpful to elucidate the heterogeneous
progression of liver cancers implying their cellular origins from different developmental
stages.
Materials and Methods
Patients and diagnosis of tumor types
We prospectively collected intrahepatic 70 HCC, 7 CHC, and 13 CC specimens from the
patients who had surgical treatment for tumor at Seoul National University (SNU) Hospital.
Intraoperative ultrasonography confirmed that no distant metastases or space-occupying
lesions existed in the non-resected remnant liver of any of the individuals in this study.
Patients with extrahepatic tumor were excluded. All the patients were determined to have
received curative resection by examining the presence of residual tumors at surgical margin.
The study protocol was approved by the institutional review board at the Seoul National
University Hospital. Histological diagnosis using H&E-stained slides were reviewed by two
experienced pathologists, independently. Validation of tumor types was performed by using
the immune-reactivity of anti-hepatocyte antibody and CK7/CK19, respectively (i.e., HCC,
+/−; CHC, +/+; CC, −/+). All CHC specimens were the mixed type C according to Allen and
Lisa classification (3).
Microarray experiments
Microarray experiments were performed using Affymetrix HGU-133A2 GeneChip as
described previously (13). Raw data of 90 tumors including our previous data (13) were
normalized by RMA method (14), and further set the mean values of each gene and each
sample to zero. For multiple tagged gene features for same Entrez Gene identifier, the gene
feature with the highest magnitude (i.e. sum of square of the expression levels) was used as
a representative gene feature.
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Construction of gene expression compendium of HCC (HCCcomp)
The gene expression compendium of HCC (HCCcomp) was constructed by collecting six
different data sets including data from LEC (i.e., data from Laboratory of Experimental
Carcinogenesis, National Cancer Institute, GSE1898 and GSE4024), GSE5975 (15), E-
TABM-36 (16), GSE9843 (17), SNU (data from Seoul National University, GSE15765),
and a new platform data for formalin-fixed, paraffin-embedded (FFPE) tumors (GSE10186)
(18). Publicly available data were downloaded from NCBI GEO or ArrayExpress databases.
Non-HCC samples in the data sets were excluded, and each dataset was normalized as
described above. Finally, 712 HCC gene expression profiles were compiled.
The signatures for stem cell-like expression traits and canonical pathways
A collection of ES-related signatures (i.e.,ES1, ES2, sox2, oct4, myc1, and myc2),
polycomb-target gene signatures (i.e., Suz2, Eed, H3K27 bound, and PRC2), and a
proliferation-related gene signature (prol) were obtained from the previous study (11). The
rat hepatoblast (HB) gene signature expressed in early fetal liver development were also
obtained from the publication site (12). The homologous human and rat genes were linked
via the NCBI HomoloGene database. For the enrichment test of canonical functions, the
gene sets in each of biological process Gene Ontology (GO) terms with at least 3 genes were
used.
Estimation of the enrichment of gene expression signatures
The enrichment of a gene set in individual tumors was determined by Kolmogorov-Smirnov
(KS-) test. Briefly, for each individual gene expression profile, two P-values for the
estimates D+ and D− were calculated by KS-test, which determine the significance of the
directional (positive or negative) enrichment of distributions of the signature. The
enrichment scores SD+ and SD− for a given signature was calculated as -log10 (P-value) from
D+ and D−, respectively. The enrichment score S was defined as SD+ if SD+ > SD− and
−SD− if SD+ < SD−. The samples with |S|>2 (P<0.01) were regarded to be significantly
enriched. The enrichment patterns across sample groups were determined by calculating
fraction of the significantly enriched samples in a group, and the significance of the group
enrichment was calculated by hypergeometric test as described previously (11).
Gene network analysis
Genetic network was constructed using PathwayStudio (Ariadne Genomics version 6.2). All
the direct interactions among an interested gene set were identified from the curated
database provided by the software. Of the subnetworks constructed from the gene set, the
largest sub-network with significant enrichment (P<0.05, calculated from the software) was
identified as a key regulatory network.
Results
Clinical and transcriptomic characteristics of CC, CHC, and HCC
The clinical features of HCC, CHC, and CC were summarized in Supplementary Table S1.
Compared with the HCC patients, the CC patients were much older (>55) and had lower
serum levels of AFP and platelets. Histologically, all the CC tumors were multiple nodular
types implying their aggressive behavior. Kaplan-Meir plot analyses revealed that the CC
patients had poorer recurrence-free survival (RFS) and overall survival (OS) compared with
those of HCC patients (Supplementary Fig. S1A, B). The CHC patients showed poor
prognosis similar to CC patients suggesting the closer likeliness of CC and CHC tumors in
agreement with previous study (19).
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First, we sought to evaluate whether the expression profiles are ready to classify the tumor
types. Unsupervised clustering analysis showed that the HCC and CC were well stratified
indicating the marked difference between HCC and CC (Supplementary Fig. S1C). 5 out of
7 CHCs were clustered together with the CC tumors supporting the prognostic similarity
between CHC and CC. No significant batch effect was found between the newly added HCC
samples and the previous ones (Supplementary Fig. S1C). Next, to verify the reflection of
the conserved tumor type characteristics in the gene expression profiles, the functional
characteristics of each tumor type was evaluated by calculating the signature enrichment in
the GO hierarchy. Considering the heterogeneity of the expression patterns in individual
tumors, the signature enrichment analysis was applied to each tumor (for details see
Materials and Methods). The HCC specimens were enriched with the metabolism- and
immune-related functions, while the CC specimens were enriched with the development/
differentiation- or metastasis/adhesion-related functions (Supplementary Fig. S2). The CHC
showed similar pattern with the CC. These data indicate that the distinct prognostic values of
each tumor class are well reflected in the gene expression patterns. Therefore, we suggest
that the prognostic differences among the tumor types are bona fide tumor characteristics
rather than the casual associations with other clinical factors such as operability of the
tumors, time to diagnosis, or patient's health condition.
Identification of a novel subtype cholangiocarcinoma-like HCC (CLHCC)
Next, to determine the expression of CC-like traits in HCC, we identified differentially
expressed genes between HCC and CC (n=2,188) by using 10,000 permuted two-sample T-
test (P<0.001) and fold difference greater than 2 (false discovery rate > 0.0023). These
genes included many putative candidates for the prognostic biomarkers as well as
biomarkers for the differential diagnosis of CC. Notably, well-known biomarkers for CC or
hepatic progenitor cells (HPC) such as KRT19 (CK19, 6.0 fold), TACSTD1 (EpCam, 4.1
fold), and PROM1 (CD133, 3.0 fold) were identified. Also, known CC biomarkers such as
CEACAM6 (20), MUC1 (21), and CLDN4 (22) were identified indicating the usefulness of
the CC signature as novel differential biomarkers for CC. Supervised clustering of the
tumors with these genes revealed that a fraction of HCC (14 out of 70) was clustered
together with CC samples. These tumors, referred to CC-like HCC (CLHCC), showed
shorter recurrence-free survival (RFS) and overall survival (OS) compared with other HCC
(P = 5.21 × 10−6, 0.004, respectively, log-rank test, Fig. 1A, B). No significant association
with clinical features was found (Supplementary Table S2).
Independent validation of the prognostic value of the CLHCC
To validate and characterize the CLHCC in independent data sets with larger sample size,
we constructed a gene expression compendium of HCC (HCCcomp, n=712) by
concatenating 6 independent HCC data sets. We defined the most differentially expressed
genes between CLHCC and other HCC as classifiers for CLHCC, which we referred to CC-
like expression trait in HCC (i.e., CC signature, n=625, false discovery rate > 0.0073,
Supplementary Table 3). Then, the HCC tumors were classified based on the expression
status of the CC signature. Since the clustering-based classification shown in Fig. 1 can be
influenced by sample composition in the data set to be tested, we calculated the individual
enrichment scores of CC signature based on KS-test. The tumors expressing both up-
(CC_UP, P<0.01) and down- (CC_DOWN, P<0.01) regulated genes were classified as C1
(representing CLHCC, n=190), while the other tumors were classified as C2 (n=522).
Notably, each subtype in the C1-C2 classification showed homogeneous expression pattern
independent of microarray platforms and patient cohorts, which may support the consistency
and robustness of our classification (Fig. 2A).
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For independent validation, the prognostic values between C1 and C2 tumors were evaluated
in two independent cohorts of Chinese (n=61) and Caucasian (n=78) patients in the LEC
data set which had been described in a previous study (5). The C1 tumors showed shorter
RFS and OS compared with the C2 tumors in both cohorts (Fig. 2B, C). In addition,
univariate and multivariate analyses in the validation data set (n=139, Table 1) and test data
set (n=70, Supplementary Table S4) also demonstrated that the C1-C2 classification is
significant in predicting RFS as well as OS. Taken together, we suggest that the CC
signature is a strong predictor for poor prognosis.
As like CC, GO analysis showed that the C1 tumors were enriched with the proliferation,
metastasis/adhesion, and development-related functions reflecting their aggressive
phenotype (Fig. 3A,B). By contrast, the C2 tumors were enriched with metabolism-related
genes which might be due to the high metabolic rate of well-differentiated hepatocyte-
derived HCC. Next, we further sought to identify key regulators of the CC signature. Of the
genes directly interacted with the CC_UP genes (n=251), the TP53 expression subnetwork
was identified as the most prominent subnetwork with significant enrichment (P=0.036)
indicating the finding is not likely to be observed by chance (Fig. 3C and Supplementary
Table S5). This result may support the regulatory role of TP53 for the aggressive phenotype
of CLHCC.
Comparison of the expression of ES and CC signatures
Considering the hypothesis that the CHC is originated from bipotential liver stem/progenitor
cells (4), we examined whether the CLHCC (C1) express stem cell-like traits. We evaluated
multiple ES-related signatures (i.e., ES1, ES2, and the target genes for Nanog, Oct4, Sox2,
and Myc) and the polycomb group target signatures (i.e., Suz2, Eed, H3K27 bound, and
PRC2 target genes) which were previously known to play important roles in maintaining the
undifferentiating status of ES cells (11, 23-27). Strikingly, the C1 tumors showed significant
enrichment of the ES signatures and combined repression of polycomb target genes (Fig.
4A). Another stemness trait, a hepatoblast–derived signature (HB signature) was also
evaluated, which showed similar expression patterns with the ES signatures. In addition, to
exclude the possible influence of the proliferation-related genes in the ES signature, we
subtracted them from the CC, HB, and ES signatures (noprol), but no significant influence
was found (Fig. 4A). When we compared the genes in these signatures, only the 36 HB
genes (5.8 %) and the 26 ES1 genes (4.2 %) were overlapped with the CC signature genes
(Supplementary Fig. S3A), implying that the prognostic difference between C1-C2 classes is
not likely to be confounded by the co- enrichment of the ES or HB signatures. As expected,
no significant influence was found on the CC signature enrichment by subtracting the HB
signature and/or ES signature genes (i.e., ES1) from the CC signature genes (i.e., CC_noHB,
CC_noES, and CC_noHBnoES) (Fig. 4B). Taking these results together, we suggest that the
prognostic value of the CC signature is independent of the coexpression of the HB, ES, or
proliferation-related genes.
For independent validation, we next evaluated the relationship between CC and ES
signatures in each data set which were compiled in HCCcomp. Remarkably, all the 6 data
sets showed significant enrichment of ES signatures in C1 tumors compared with C2
tumors. These findings strongly indicate the robustness and consistency of the coexpression
of CC and ES signatures regardless of microarray platforms and patient cohorts (Fig. 4C).
Next, when we further examined the individual tumors, not all the C1 tumors coexpress the
ES signature (Supplementary Fig. S3B). This may imply the distinct expression of CC and
ES signatures to some extent, which might be derived from intermediate cellular origins
during the sequential development stages from the primitive liver stem cells to biliary
committed cells. With this concern, we investigated whether the combined expression status
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of ES and CC signature can reflect distinct prognostic phenotypes. The HB signature was
not considered in the analysis because of its intermediate property between ES and CC
signature. When we re-classified the 209 tumors (LEC and SNU) which survival data are
available into four classes based on the expression of CC and ES signatures (i.e., CC+ES+,
CC+ES−, CC−ES+, and CC−ES−), the CC+ES+ tumors showed the worst prognosis for both
RFS (hazard ratio, HR=2.84; 95% CI =1.51−5.34; P=7.42 x 10−4) and OS (HR=2.98; 95%
CI=1.79−4.98; P=1.2 × 10−5) compared with the CC−ES− showing the best prognosis (Fig.
4D). The CC+ES− (n=21) and CC−ES+ (n=26) tumors showed intermediate prognostic
values indicating the correlation between prognostic outcomes and the expression status of
the CC and ES signatures. Although further validation might be required, this finding may
support the idea that the cellular origin at different developmental stage plays a pivotal role
in the heterogeneous clinical outcome of HCC.
Discussion
In this study, we addressed the heterogeneity of HCC by identifying a fraction of HCC
expressing the CC-like traits. Although we profiled relatively small samples of CC, the huge
expression difference between CC and HCC (as like “apple and orange”) allowed us to
identify the robust CC signature. The functional and clinical relevance of the CC signature
could be further validated by independent data sets (Fig. 2B, C).
The CC signature was concomitantly expressed with the ES or HB signatures suggesting the
stem-like features of CLHCC, which could be validated by all the 6 independent HCC data
sets. In fact, biliary markers such as CK-7 and CK-19 are frequently used as HPC markers
(10, 28, 29). Therefore, the expression of stem-like traits or biliary traits alone may not be
specific in discriminating the stem cell origin tumors from the biliary cell origin tumors.
Further evaluation using HCCcomp revealed the presence of CC+ES− or CC−ES+ tumors,
indicating the existence of intermediate transition of the expression of those signatures. The
ES signature is presumed to be derived from more primitive and pluripotent stem cells. The
HB signature may express in the tumors derived from hepatoblast cells, whereas the CC
signature may express in the tumors derived from the biliary lineage cells including
premature and mature cholangiocytes. Based on this concept, the cellular origin of HCC
from the sequential development stages can be postulated by the expression status of the ES,
HB, and CC signatures as illustrated in Supplementary Fig. S4. This suggests the different
cellular origin of HCC during transition from pluripotent to differentiated CC or HCC may
play a critical role in the heterogeneous progression of HCC. However, we cannot exclude
the possibility that trans-differentiation and de-differentiation of hepatocytes or
cholangiocytes during cancer development can contribute to the acquisition of these
signatures.
Our analysis dissecting the heterogeneous HCC based on the expression of CC signature
could classify the tumors into homogeneous and distinct prognostic phenotypes. Targeting
molecular pathways specific to such subpopulations would be more effective for the
development of personalized clinical strategy (30). We suggested TP53 pathway may play a
pivotal role in the development of the CC signature-expressing HCC (CLHCC). The
association of TP53 mutation with poor prognosis is well known in many cancer types
(reviewed in 31). Moreover, recent studies have demonstrated the critical role of TP53 in the
control of neural and glioma stem/progenitor cell renewal and differentiation (32, 33). These
findings consistently support the pivotal role of TP53 in the aggressive progression of the
HCC harboring CC-like or stem-like traits.
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In conclusion, our findings provide novel biological and clinical insights into the CC-like
traits in HCC, emphasizing the critical role of the developmental stage of the cell of origin in
HCC pathogenesis.
Supplementary Material
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Abbreviations
CC cholangiocarcinoma
HCC hepatocellular carcinoma
CHC combined hepatocellular-cholangiocarcinoma
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ES embryonic stem
HPC hepatic progenitor cell
CLHCC cholangiocarcinoma-like hepatocellular carcinoma
HB hepatoblast
HCCcomp gene expression compendium of HCC
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Fig. 1. Identification of cholangiocarcinoma-like HCC (CLHCC)
A. Supervised clustering of CC, CHC, and HCC based on the expression of the CC signature
(left). The top 20 most differential expressed genes between CC and HCC are indicated
(right). B. Kaplan-Meir plot analyses for recurrence-free survival (RFS) and overall survival
(OS) between HCC and CLHCC.
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Fig. 2. Validation of the CC signature in HCCcomp
A. The gene expression profiles of HCCcomp were classified into 2 groups based on the
expression of the CC signature (top). The enrichment scores for CC_UP and CC_DOWN
signatures are shown (bottom). B, C. Kaplan-Meir plots for recurrence-free survival (RFS,
left) and overall survival (OS, right) in independent cohorts of Chinese (n=61, B) and
Caucasian (n=78, C), respectively. The follow up time for recurrence-free survival (RFS)
and overall survival (OS) are truncated to five years.
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Fig. 3. Functional characteristics of the CC signature
A. The functional enrichment scores in the Gene Ontology hierarchy for each group C1 and
C2. A total of 196 GO terms are significantly enriched at least in a group (P<0.01,
hypergeometric test). B. The enrichment scores in each group are shown by bar-views (right
bar). The enriched patterns of the GO terms for the 4 functional categories are indicated by
different colors, respectively (the rightmost bar). The 4 functional categories are chosen
which show prominent enrichment of the enrichment scores in each group. Other GO terms
which are not prominent in the functional grouping are indicated as “unclassified”. C.
Network analysis indicates the TP53 as a most prominent regulator of the CC_UP signature
with significant enrichment (P<0.036).
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Fig. 4. Comparison of the CC signature with ES signatures
A. The enrichment of ES signatures and polycomb target gene sets in C1 and C2 classes in
HCCcomp are shown. The enrichment scores of ES signatures without proliferation
signature (no_prol) are shown (right bar). B. Bar plots for the enrichment scores of the
CC_UP (top) and CC_DOWN (bottom) signatures and the CC_UP and CC_DOWN
signatures subtracted by ES (noES), HB (noHB), or ES and HB (noESnoHB) are shown. C.
The enrichment ES signatures in 6 independent data sets are shown. For each data set, the
group enrichment in C1 and C2 tumors are indicated in the right bars (P<0.05). D. Kaplan-
Meir plots analyses for recurrence-free survival (RFS, left) and overall survival (OS, right)
based on the expression status of CC and ES signatures in the integrated LEC and SNU data
sets (n=209). The CC+ represents C1 tumors, and ES+ represents the tumors express ES1
signature.
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